Look Out Below! AP Pharma’s (APPA) Drug “APF530” Denied Approval from FDA
AP Pharma, Inc. had a great day yesterday closing up 32.05% at $2.06 on strong volume of 6,300,000 traded shares in anticipation of news from the FDA on its leading drug candidate, “APF530”. APF 530 is developed for the prevention of both acute and delayed-onset chemotherapy nausea-induced vomiting (CNIV). AP530 contains granisetron, which has been approved in both oral and injections for immediate onset of CNIV, but not for delayed-onset. The granisetron is formulated with AP’s proprietary Biochronomer™ delivery system which allows drug levels to be maintained for 5 days from a single injection. AP Pharma had reported positive results…